A Critical Review of Electroporation As a Plasmid Delivery System in Mouse Skeletal Muscle
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Gene Use Restriction Technologies for Transgenic Plant Bioconfinement
Plant Biotechnology Journal (2013) 11, pp. 649–658 doi: 10.1111/pbi.12084 Review article Gene use restriction technologies for transgenic plant bioconfinement Yi Sang, Reginald J. Millwood and C. Neal Stewart Jr* Department of Plant Sciences, University of Tennessee, Knoxville, TN, USA Received 1 February 2013; Summary revised 3 April 2013; The advances of modern plant technologies, especially genetically modified crops, are considered accepted 9 April 2013. to be a substantial benefit to agriculture and society. However, so-called transgene escape *Correspondence (fax 1-865-974-6487; remains and is of environmental and regulatory concern. Genetic use restriction technologies email [email protected]) (GURTs) provide a possible solution to prevent transgene dispersal. Although GURTs were originally developed as a way for intellectual property protection (IPP), we believe their maximum benefit could be in the prevention of gene flow, that is, bioconfinement. This review describes the underlying signal transduction and components necessary to implement any GURT system. Keywords: transgenic plants, Furthermore, we review the similarities and differences between IPP- and bioconfinement- transgene escape, male sterility, oriented GURTs, discuss the GURTs’ design for impeding transgene escape and summarize embryo sterility, transgene deletion, recent advances. Lastly, we go beyond the state of the science to speculate on regulatory and gene flow. ecological effects of implementing GURTs for bioconfinement. Introduction proposed (Daniell, 2002; Gressel, 1999; Moon et al., 2011), including strategies for male sterility (Mariani et al., 1990), Transgenic crops have become an integral part of modern maternal inheritance (Daniell et al., 1998; Iamtham and Day, agriculture and have been increasingly adopted worldwide (James, 2000; Ruf et al., 2001), transgenic mitigation (Al-Ahmad et al., 2011). -
Widespread Gene Transfection Into the Central Nervous System of Primates
Gene Therapy (2000) 7, 759–763 2000 Macmillan Publishers Ltd All rights reserved 0969-7128/00 $15.00 www.nature.com/gt NONVIRAL TRANSFER TECHNOLOGY RESEARCH ARTICLE Widespread gene transfection into the central nervous system of primates Y Hagihara1, Y Saitoh1, Y Kaneda2, E Kohmura1 and T Yoshimine1 1Department of Neurosurgery and 2Division of Gene Therapy Science, Department of Molecular Therapeutics, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan We attempted in vivo gene transfection into the central ner- The lacZ gene was highly expressed in the medial temporal vous system (CNS) of non-human primates using the hem- lobe, brainstem, Purkinje cells of cerebellar vermis and agglutinating virus of Japan (HVJ)-AVE liposome, a newly upper cervical cord (29.0 to 59.4% of neurons). Intrastriatal constructed anionic type liposome with a lipid composition injection of an HVJ-AVE liposome–lacZ complex made a similar to that of HIV envelopes and coated by the fusogenic focal transfection around the injection sites up to 15 mm. We envelope proteins of inactivated HVJ. HVJ-AVE liposomes conclude that the infusion of HVJ-AVE liposomes into the containing the lacZ gene were applied intrathecally through cerebrospinal fluid (CSF) space is applicable for widespread the cisterna magna of Japanese macaques. Widespread gene delivery into the CNS of large animals. Gene Therapy transgene expression was observed mainly in the neurons. (2000) 7, 759–763. Keywords: central nervous system; primates; gene therapy; HVJ liposome Introduction ever, its efficiency has not been satisfactory in vivo. Recently HVJ-AVE liposome, a new anionic-type lipo- Despite the promising results in experimental animals, some with the envelope that mimics the human immuno- gene therapy has, so far, not been successful in clinical deficiency virus (HIV), has been developed.13 Based upon 1 situations. -
Recombinant DNA and Elements Utilizing Recombinant DNA Such As Plasmids and Viral Vectors, and the Application of Recombinant DNA Techniques in Molecular Biology
Fact Sheet Describing Recombinant DNA and Elements Utilizing Recombinant DNA Such as Plasmids and Viral Vectors, and the Application of Recombinant DNA Techniques in Molecular Biology Compiled and/or written by Amy B. Vento and David R. Gillum Office of Environmental Health and Safety University of New Hampshire June 3, 2002 Introduction Recombinant DNA (rDNA) has various definitions, ranging from very simple to strangely complex. The following are three examples of how recombinant DNA is defined: 1. A DNA molecule containing DNA originating from two or more sources. 2. DNA that has been artificially created. It is DNA from two or more sources that is incorporated into a single recombinant molecule. 3. According to the NIH guidelines, recombinant DNA are molecules constructed outside of living cells by joining natural or synthetic DNA segments to DNA molecules that can replicate in a living cell, or molecules that result from their replication. Description of rDNA Recombinant DNA, also known as in vitro recombination, is a technique involved in creating and purifying desired genes. Molecular cloning (i.e. gene cloning) involves creating recombinant DNA and introducing it into a host cell to be replicated. One of the basic strategies of molecular cloning is to move desired genes from a large, complex genome to a small, simple one. The process of in vitro recombination makes it possible to cut different strands of DNA, in vitro (outside the cell), with a restriction enzyme and join the DNA molecules together via complementary base pairing. Techniques Some of the molecular biology techniques utilized during recombinant DNA include: 1. -
REVIEW Gene Therapy
Leukemia (2001) 15, 523–544 2001 Nature Publishing Group All rights reserved 0887-6924/01 $15.00 www.nature.com/leu REVIEW Gene therapy: principles and applications to hematopoietic cells VFI Van Tendeloo1,2, C Van Broeckhoven2 and ZN Berneman1 1Laboratory of Experimental Hematology, University of Antwerp (UIA), Antwerp University Hospital (UZA), Antwerp; and 2Laboratory of Molecular Genetics, University of Antwerp (UIA), Department of Molecular Genetics, Flanders Interuniversity Institute for Biotechnology (VIB), Antwerp, Belgium Ever since the development of technology allowing the transfer Recombinant viral vectors of new genes into eukaryotic cells, the hematopoietic system has been an obvious and desirable target for gene therapy. The last 10 years have witnessed an explosion of interest in this Biological gene transfer methods make use of modified DNA approach to treat human disease, both inherited and acquired, or RNA viruses to infect the cell, thereby introducing and with the initiation of multiple clinical protocols. All gene ther- expressing its genome which contains the gene of interest (= apy strategies have two essential technical requirements. ‘transduction’).1 The most commonly used viral vectors are These are: (1) the efficient introduction of the relevant genetic discussed below. In each case, recombinant viruses have had material into the target cell and (2) the expression of the trans- gene at therapeutic levels. Conceptual and technical hurdles the genes encoding essential replicative and/or packaging pro- involved with these requirements are still the objects of active teins replaced by the gene of interest. Advantages and disad- research. To date, the most widely used and best understood vantages of each recombinant viral vector are summarized in vectors for gene transfer in hematopoietic cells are derived Table 1. -
Gene Therapy and Genetic Engineering: Frankenstein Is Still a Myth, but It Should Be Reread Periodically
Indiana Law Journal Volume 48 Issue 4 Article 2 Summer 1973 Gene Therapy and Genetic Engineering: Frankenstein is Still a Myth, but it Should be Reread Periodically George A. Hudock Indiana University - Bloomington Follow this and additional works at: https://www.repository.law.indiana.edu/ilj Part of the Genetics and Genomics Commons Recommended Citation Hudock, George A. (1973) "Gene Therapy and Genetic Engineering: Frankenstein is Still a Myth, but it Should be Reread Periodically," Indiana Law Journal: Vol. 48 : Iss. 4 , Article 2. Available at: https://www.repository.law.indiana.edu/ilj/vol48/iss4/2 This Article is brought to you for free and open access by the Law School Journals at Digital Repository @ Maurer Law. It has been accepted for inclusion in Indiana Law Journal by an authorized editor of Digital Repository @ Maurer Law. For more information, please contact [email protected]. GENE THERAPY AND GENETIC ENGINEERING: FRANKENSTEIN IS STILL A MYTH, BUT IT SHOULD BE REREAD PERIODICALLY GEORGE A. HUDOCKt Biotechnology and the law are far removed from each other as disciplines of human intellect. Yet the law and my own discipline, genetics, have come together in many courtrooms concerning such matters as paternity, and they will continue to intersect with increasing frequency as the visions of 100 years ago become the reality of today. This article examines the implications of recent research for human genetic therapy and genetic engineering, and suggests some guidelines for legal regulation of genetic technology. The following discussion derives from three premises which I view as basic: (1) that which is currently possible in genetic engineering, and in fact has already been done, is generally underestimated; (2) what may be possible in the near future is quite commonly overesti- mated; (3) regulation of the application of genetic technology is possible and will not be overwhelmingly complicated. -
Gibson Assembly Cloning Guide, Second Edition
Gibson Assembly® CLONING GUIDE 2ND EDITION RESTRICTION DIGESTFREE, SEAMLESS CLONING Applications, tools, and protocols for the Gibson Assembly® method: • Single Insert • Multiple Inserts • Site-Directed Mutagenesis #DNAMYWAY sgidna.com/gibson-assembly Foreword Contents Foreword The Gibson Assembly method has been an integral part of our work at Synthetic Genomics, Inc. and the J. Craig Venter Institute (JCVI) for nearly a decade, enabling us to synthesize a complete bacterial genome in 2008, create the first synthetic cell in 2010, and generate a minimal bacterial genome in 2016. These studies form the framework for basic research in understanding the fundamental principles of cellular function and the precise function of essential genes. Additionally, synthetic cells can potentially be harnessed for commercial applications which could offer great benefits to society through the renewable and sustainable production of therapeutics, biofuels, and biobased textiles. In 2004, JCVI had embarked on a quest to synthesize genome-sized DNA and needed to develop the tools to make this possible. When I first learned that JCVI was attempting to create a synthetic cell, I truly understood the significance and reached out to Hamilton (Ham) Smith, who leads the Synthetic Biology Group at JCVI. I joined Ham’s team as a postdoctoral fellow and the development of Gibson Assembly began as I started investigating methods that would allow overlapping DNA fragments to be assembled toward the goal of generating genome- sized DNA. Over time, we had multiple methods in place for assembling DNA molecules by in vitro recombination, including the method that would later come to be known as Gibson Assembly. -
Gene Delivery & Expression
GENE DELIVERY & EXPRESSION GENE DELIVERY & EXPRESSION LENTIVIRUS, PIGGYBAC, MINICIRCLES, AND MORE SYSTEMBIO.COM SYSTEMS FOR ANY APPLICATION: LENTIVIRAL TOOLS AND MORE In today’s busy labs, getting experiments to work right the first time is critical—not only do you want results you can trust, you want them fast. Which is why SBI has spent over a decade developing a range of exceptionally high-performing products for gene delivery and expression. From our popular high-titer lentivirus production tools to the latest in AAV-based gene delivery systems and a range of reliable integrating and non- integrating gene expression vectors, SBI delivers high-quality, cutting-edge products and services for mammalian gene delivery and expression. With products and services that have been used in thousands of peer-reviewed papers, SBI is your trusted partner for high-quality research. 04 06 12 14 PRODUCT INTEGRATING NON-INTEGRATING SERVICES SELECTOR VECTOR SYSTEMS VECTOR SYSTEMS Syn2Clone Lentiviral Enhanced Episomal Virus Packaging Vectors PiggyBac Cell Line Construction Transposon Minicircle Technology PhiC31 Integrase AAV PinPoint Targeted Integration Non-integrating Lentiviral Gene Knock-out Gene Knock-in Gene Edit AAVS1 Safe Harbor Site INDELS via NHEJ NN OR HR Donor HR Donor Vector Vector HR Donor Vector GENE INSERTION loxP loxP (with HR vector) Excision of GENE KNOCK-OUT selection cassette (with HR vector) CORRECTED GOI PRODUCT SELECTOR A WEALTH OF OPTIONS FOR GENE DELIVERY AND EXPRESSION Integrating Vectors With integrating vectors, the vector DNA becomes permanently incorporated into the genome, often at multiple copy numbers. Depending on the system, integration can be random or directed to a specific locus. -
World Resources Institute the Monsanto Company
World Resources Institute Sustainable Enterprise Program A program of the World Resources Institute The Monsanto Company: Quest for Sustainability (A) “Biotechnology represents a potentially sustainable For more than a decade, WRI's solution to the issue, not only of feeding people, but of providing Sustainable Enterprise Program (SEP) the economic growth that people are going to need to escape has harnessed the power of business to poverty…… [Biotechnology] poses the possibility of create profitable solutions to leapfrogging the industrial revolution and moving to a post- environment and development industrial society that is not only economically attractive, but challenges. BELL, a project of SEP, is also environmentally sustainable.i ” focused on working with managers and academics to make companies --Robert Shapiro, CEO, Monsanto Company more competitive by approaching social and environmental challenges as unmet market needs that provide Upon his promotion to CEO of chemical giant The business growth opportunities through Monsanto Company in 1995, Robert Shapiro became a vocal entrepreneurship, innovation, and champion of sustainable development and sought to redefine the organizational change. firm’s business strategy along principles of sustainability. Shapiro’s rhetoric was compelling. He captured analysts’ Permission to reprint this case is attention with the specter of mass hunger and environmental available at the BELL case store. degradation precipitated by rapid population growth and the Additional information on the Case -
Quick and Efficient Method for Genetic Transformation of Biopolymer
Technical Note Received: 29 July 2009 Revised: 14 September 2009 Accepted: 14 September 2009 Published online in Wiley Interscience: 29 October 2009 (www.interscience.wiley.com) DOI 10.1002/jctb.2284 Quick and efficient method for genetic transformation of biopolymer-producing bacteria Qin Wang,a Alexander P. Mueller,a Chean Ring Leong,b Ken’ichiro Matsumoto,b Seiichi Taguchib and Christopher T. Nomuraa∗ Abstract In order to genetically modify microorganisms capable of producing polyhydroxyalkanoate (PHA) biopolymers, a simple and rapid method to prepare freshly plated Pseudomonas cells for transformation via electroporation was developed. This method can be used to transfer both replicative plasmids and linear DNA to knock out genes into the cells. The transformation efficiencies were in the range of ≥107 transformants µg−1 DNA for replicative plasmids and ≥106 transformants µg−1 DNA for linear DNA, which are comparable with commercially available competent cells. Furthermore, this transformation procedure can be performed in less than 10 min, saving a great deal of time compared with traditional methods. Knockout mutants of several Pseudomonas species were generated by transformation of linear DNA and these mutations were verified by PCR and analysis of PHA content. c 2009 Society of Chemical Industry Keywords: transformation; electroporation; Pseudomonas putida; polyhydroxyalkanoates (PHAs) INTRODUCTION using various strains of P. putida.StrainsweregrowninLuria- Pseudomonas putida is a Gram-negative soil bacterium that plays Bertani (LB) medium (1% tryptone, 0.5% yeast extract, and 0.5% animportantroleinelementcycling innature,bioremediation,and NaCl) with the appropriate antibiotic when necessary. For selection production of polyhydroxyalkanoates (PHAs), which are environ- of transformants, kanamycin (Km) and gentamycin (Gm) were mentally friendly biodegradable plastics.1–3 Despite having a fully added to LB agar plates and liquid media at final concentrations sequenced genome,3 the functions of many ORFs in this organ- of 50 µgmL−1 and 20 µgmL−1, respectively. -
ES Cell Targeting Handbook
TABLE OF CONTENTS Overview of ES Core Facility Introduction Generation of Gene-Targeted ES Cells Karyotyping of Positive ES Clones ES Cell Request Form General Information for the Generation of Targeted Cells Principles of Gene Targeting Requirements for the Design of Targeting Constructs Screening Assay for the Identification of Targeted ES Clones Overview of ES Cell Culture ES Cell Factors Affecting Successful Chimera Production FAQ Overview of ES Core Facility Our Mission The ES Core Facility (ECF) was founded by the NINDS Core Center Grant and was established to benefit the contributors of this proposal. The mission of ECF is to effectively produce ES cell lines with a high probability of germline transmission. Core Service Services provided by the Core for a typical project include: • Provide guidance on the design of targeting construct • Generate targeted ES cell lines for the production of chimeric mice • Karyotyping ES cells to be micro-injected into blastocysts Consultation is available from ECF directors and staff members on the entire procedures of generating gene knock-out mice. Application for Service Prior to the initiation of a project, a brief meeting is generally required between the investigator and ECF facility staff resulting in a mutually acceptable research strategy. This strategy will outline specifics of the project including knockout strategy, KO construct design, screening assays, and other procedural issues relevant to the generation of targeted ES cells. In addition, a completed service application form, signed by the principal investigator and approved by the Core Director, will also be required. The Core Director will prioritize the service requests according to the difficulty of the project and work load. -
Intramuscular Electroporation Delivery of IFN- Gene Therapy for Inhibition of Tumor Growth Located at a Distant Site
Gene Therapy (2001) 8, 400–407 2001 Nature Publishing Group All rights reserved 0969-7128/01 $15.00 www.nature.com/gt RESEARCH ARTICLE Intramuscular electroporation delivery of IFN-␣ gene therapy for inhibition of tumor growth located at a distant site S Li, X Zhang, X Xia, L Zhou, R Breau, J Suen and E Hanna Department of Otolaryngology/Head and Neck Surgery, University of Arkansas School of Medicine, 4001 W Capital Avenue, Little Rock, AR 72205, USA Although electroporation has been shown in recent years to 2 or endostatin gene, also delivered by electro-injection. The be a powerful method for delivering genes to muscle, no increased therapeutic efficacy was associated with a high gene therapy via electro-injection has been studied for the level and extended duration of IFN-␣ expression in muscle treatment of tumors. In an immunocompetent tumor-bearing and serum. We also discovered that the high level of IFN-␣ murine model, we have found that delivery of a low dose of expression correlated with increased expression levels of reporter gene DNA (10 g) to muscle via electroporation the antiangiogenic genes IP-10 and Mig in local tumor under specific pulse conditions (two 25-ms pulses of 375 tissue, which may have led to the reduction of blood vessels V/cm) increased the level of gene expression by two logs of observed at the local tumor site. Delivery of increasing doses magnitude. Moreover, administration of 10 g of interferon (10–100 g) of IFN-␣ plasmid DNA by injection alone did (IFN)-␣ DNA plasmid using these parameters once a week not increase antitumor activity, whereas electroporation for 3 weeks increased the survival time and reduced squam- delivery of increasing doses (10–40 g) of IFN-␣ plasmid ous cell carcinoma (SCC) growth at a distant site in the DNA did increase the survival time. -
The Transgenic Core Facility
Genetic modification of the mouse Ben Davies Wellcome Trust Centre for Human Genetics Genetically modified mouse models • The genome projects have provided us only with a catalogue of genes - little is know regarding gene function • Associations between disease and genes and their variants are being found yet the biological significance of the association is frequently unclear • Genetically modified mouse models provides a powerful method of assaying gene function in the whole organism Sequence Information Human Mutation Gene of Interest Mouse Model Reverse Genetics Phenotype Gene Function How to study gene function Human patients: • Patients with gene mutations can help us understand gene function • Human’s don’t make particularly willing experimental organisms • An observational science and not an experimental one • Genetic make-up of humans is highly variable • Difficult to pin-point the gene responsible for the disease in the first place Mouse patients: • Full ability to manipulate the genome experimentally • Easy to maintain in the laboratory – breeding cycle is approximately 2 months • Mouse and human genomes are similar in size, structure and gene complement • Most human genes have murine counterparts • Mutations that cause disease in human gene, generally produce comparable phentoypes when mutated in mouse • Mice have genes that are not represented in other model organisms e.g. C. elegans, Drosophila – genes of the immune system What can I do with my gene of interest • Gain of function – Overexpression of a gene of interest “Transgenic